Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 14,941 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Not listed Phase 2 Interventional

Secretin for Acute Pancreatitis

NCT03686618
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

NCT02829918
View directory record Official record
Conditions
Biliary Tract Cancer, Biliary Tract Neoplasms
Interventions
Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn

NCT05363618
View directory record Official record
Conditions
Heartburn
Interventions
Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml), Placebo 1.4 ml
Dietary Supplement · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 26, 2026, 2:51 PM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 26, 2026, 2:51 PM EDT
Recruiting Phase 1 Interventional

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Interventions
PT0511, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NCT01466374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, BMS-936557 (Anti-IP-10 Antibody)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 26, 2026, 2:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Tirzepatide Impact Assessment Study

NCT07740291
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
Interventions
GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NCT01015118
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms
Interventions
Placebo, Paclitaxel, BIBF 1120, Carboplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553591
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
257
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Not applicable Interventional

Evaluation of the Ability to Detect Bowel Gas During Laparoscopic Surgery

NCT02679118
View directory record Official record
Conditions
Intestinal Perforation
Interventions
Sentire
Device
Lead sponsor
Dan E. Azagury
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 26, 2026, 2:51 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

NCT05223218
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Melanoma
Interventions
Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Other
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 26, 2026, 2:51 PM EDT
Completed No phase listed Observational

Connecting Audio and Radio Sensing Systems to Improve Care at Home

NCT05344950
View directory record Official record
Conditions
Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Audio + Radio (AURA)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

NCT01221818
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
E6007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 26, 2026, 2:51 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mechano-physiological Approach to Anorectal Function

NCT00219518
View directory record Official record
Conditions
Constipation
Interventions
defecography
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 26, 2026, 2:51 PM EDT
Completed No phase listed Observational

History of Hepatitis C in Volunteer Blood Donors

NCT00001982
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 2:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
Interventions
CB-103
Drug
Lead sponsor
Cellestia Biotech AG
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Santa Monica, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 26, 2026, 2:51 PM EDT
Withdrawn Not applicable Interventional

Head to Head Comparison of Two Needles EUS Guided FNB

NCT02534246
View directory record Official record
Conditions
Pancreatic Tumor
Interventions
Ultrasound biopsy needle Echo Tip ProCore, Ultrasound biopsy needle SharkCore
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 26, 2026, 2:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Encorafenib, Cetuximab, Pembrolizumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 2:51 PM EDT
Completed No phase listed Observational

Hormonal Influences on Inflammatory Bowel Diseases

NCT05610527
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Contraception, Menstrual Problem
Interventions
Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 26, 2026, 2:51 PM EDT
Withdrawn No phase listed Observational

Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma

NCT03748927
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 26, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

NCT01187186
View directory record Official record
Conditions
Liver Disease
Interventions
ASP1941
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 69 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Oct 26, 2026, 2:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Erythromycin in GER-Associated Apnea of the Newborn

NCT01825473
View directory record Official record
Conditions
Gastroesophageal Reflux, Apnea, Bradycardia
Interventions
Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W)
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Days and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 26, 2026, 2:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alpha-1 Foundation Research Registry

NCT00499941
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
6,655 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 26, 2026, 2:51 PM EDT
Terminated Not applicable Interventional Results available

Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents

NCT02673541
View directory record Official record
Conditions
Pancreatic Necrosis
Interventions
AXIOS™ stent, Double Pigtail Stents
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 26, 2026, 2:51 PM EDT